https://www.selleckchem.com/products/iox2.html
Using SWATH-MS analysis, we found 13 proteins to be unique in T2DM patients with early LAC. Two serum proteins were further validated by PRM-MS analysis, namely, pregnancy-zone protein (PZP) and insulin-like growth factor binding protein 3 (IGFBP3). Furthermore, the diagnostic values of these proteins were validated by ELISA, and PZP was validated as a novel serum biomarker for screening LAC in T2DM patients. Our findings indicated that PZP could be used as a novel serum biomarker for the identification of LAC in T2DM patients, which will
Like
Comment
Share
